Ardelyx scraps PhIII drug after researchers raise a safety issue for hyperkalemia patients
The roller coaster ride at Ardelyx is continuing today with news that one of their late-stage assets is being scrapped.
With their lead drug tenapanor …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
